Search clinical trials for: cetuximab and savolitinib

Total 269630 results

Hutchison Medipharma Limited

Completed

A Pharmacokinetic and Bioequivalence Study of Savolitinib Tablets in Healthy Chinese Male Volunteers

Bioequivalence

China
National Cancer Institute (NCI)

Terminated

Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal Cancer

Colorectal Carcinoma | Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage III Colon Cancer AJCC v8 | Stage III Rectal Cancer AJCC v8 | Stage IIIA Colon Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Colon Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage... and other conditions

United States
Yale University

Withdrawn

Cetuximab and Savolitinib Treatment of Ras Wild-Type Colorectal Cancer

Colorectal Cancer
Queen Mary University of London
AstraZeneca; Vall d'Hebron Institute of Oncology

Active, not recruiting

MEDI4736 Combinations in Metastatic Renal Cell Carcinoma (CALYPSO)

Renal Clear Cell Carcinoma | Renal Papillary Cell Carcinoma

United Kingdom
Hutchison Medipharma Limited

Recruiting

Savolitinib for Treating Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Patients

Non-small Cell Lung Cancer Metastatic

China
AstraZeneca

Not yet recruiting

A Positron-emission Tomography Study to Determine Brain Exposure of [11C]Savolitinib in Healthy Volunteers

Healthy Volunteers

Sweden
Hutchison Medipharma Limited

Recruiting

Savolitinib for Treating Gastric Cancer and Esophagogastric Junction Adenocarcinoma Patients

Gastric Cancer | Esophagogastric Junction Disorder

China
AstraZeneca
SCRI Development Innovations, LLC

Completed

A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC)

Papillary Renal Cell Cancer

United States, Canada, United Kingdom, Spain
Hutchison Medipharma Limited

Active, not recruiting

A Phase II Study of HMPL-504 in Lung Sarcomatoid Carcinoma and Other Non-small Cell Lung Cancer

Lung Sarcomatoid Carcinoma

China
AstraZeneca
Quotient Sciences

Completed

Absolute Bioavailability and ADME Study of Savolitinib in Healthy Male Subjects

Cancer

United Kingdom
AstraZeneca

Active, not recruiting

A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC (CoC)

Non-Small Cell Lung Cancer

United States, Argentina, India, Taiwan, Thailand, Vietnam
AstraZeneca
Hutchinson MediPharma (HMP)

Active, not recruiting

Savolitinib vs. Sunitinib in MET-driven PRCC.

Kidney Neoplasms | Carcinoma, Renal Cell | Urologic Neoplasms | Neoplasms by Site | Kidney Diseases | Carcinoma | Enzyme Inhibitors | Protein Kinase Inhibitors

United States, Italy, France, Korea, Republic of, Brazil, Russian Federation, Ukraine
Hutchison Medipharma Limited

Recruiting

Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC (SANOVO)

Non-small Cell Lung Cancer

China
Northwell Health

Terminated

Super-Selective Intraarterial Infusion of Cetuximab (Erbitux) With or Without Radiation Therapy for the Treatment of Unresectable Recurrent Squamous Cell Carcinoma of the Head and Neck

Carcinoma, Squamous Cell | Carcinoma, Squamous Cell of Head and Neck

United States
Samsung Medical Center

Completed

Study of AZD6094 (Volitinib) in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Third-line Treatment

Advanced Gastric Adenocarcinoma

Korea, Republic of
AstraZeneca

Suspended

Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC (SOUND)

Lung Cancer

China
Jeeyun Lee

Recruiting

Ph2 Study of Savolitinib and Durvalumab (MEDI4736) Combination in Advanced MET Amplified Gastric Cancer(VIKTORY-2)

Stomach Cancer, Adenocarcinoma

Korea, Republic of
Hutchison Medipharma Limited
Monash University; Sir Charles Gairdner Hospital; Austin Hospital, Melbourne...

Completed

Phase I Study of the Volitinib (HMPL-504) in Patients With Advanced Solid Tumors (HMPL-504)

Tumor

Australia
Hutchison Medipharma Limited

Completed

Phase I Study of the Volitinib (HMPL-504) in Patients With Advanced Solid Tumors (HMPL-504)

Tumors

China
Hutchison Medipharma Limited

Completed

A Food Effect Phase I Study of the Volitinib in Healthy Subjects (HMPL-504)

Food Effect | Health Subjects

China
AstraZeneca

Recruiting

Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment (SAFFRON)

Carcinoma | Non-Small-Cell Lung

China, Israel, Spain, United States, Canada, Italy, Korea, Republic of, Belgium, Bulgaria, Vietnam, Japan, United Kingdom, Brazil, France, Philippines, Taiwan, Thailand, Germany, Poland, Austria, Greece, Turkey, Argentina, Hong Kong, Chile and more
AstraZeneca

Recruiting

Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC (SAMETA)

Papillary Renal Cell Carcinoma

China, Czechia, Israel, Netherlands, Spain, United Kingdom, Korea, Republic of, Italy, India, Mexico, Turkey, Argentina, Australia, Germany, Russian Federation, Taiwan, United States, Poland, Brazil, Chile, Hong Kong, Ukraine, Canada, Franc... and more
The First Affiliated Hospital of Guangzhou Medical...

Recruiting

Savolitinib Plus Docetaxel as 2L in EGFR/ALK/ROS1/MET ex14m-wildtype NSCLC With MET Overexpression

Non-small Cell Lung Cancer

China
Guangdong Association of Clinical Trials

Active, not recruiting

Osimertinib With or Without Savolitinib as 1L in de Novo MET+, EGFR+ NSCLC (FLOWERS)

Carcinoma, Non-Small-Cell Lung

China
Celgene

Active, not recruiting

A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Participants With Advanced Solid and Hematologic Cancers

Neoplasms

United States, France, Australia, Canada, Italy, Korea, Republic of, Spain, United Kingdom
University Medical Center Groningen
UMC Utrecht; Erasmus Medical Center

Recruiting

Image Guided Surgery for Margin Assessment of Head and Neck Cancer Using Cetuximab-IRDye800CW cONjugate (ICON)

Head and Neck Squamous Cell Carcinoma | Margin Assessment

Netherlands
AstraZeneca

Active, not recruiting

AZD9291 in Combination With Ascending Doses of Novel Therapeutics

Advanced Non Small Cell Lung Cancer

Canada, Poland, Taiwan, United States, Korea, Republic of, Japan, Russian Federation, Ukraine
Amsterdam UMC, location VUmc
Radboud University Medical Center; University Medical Center Groningen

Terminated

Image Guided Treatment Optimization With Cetuximab for Patients With Metastatic Colorectal Cancer (IMPACT-CRC)

Metastatic Colorectal Cancer

Netherlands
West China Hospital
First Affiliated Hospital of Chongqing Medical University

Recruiting

First-line mCapOX+Cetuximab vs. mFOLFOX6+Cetuximab for Metastatic Left-sided CRC With Wild-type RAS/BRAF Genes (CAPCET)

Colo-rectal Cancer | Capecitabine | Cetuximab

China
Eben Rosenthal
National Cancer Institute (NCI)

Terminated

Cetuximab-IRDye 800CW and Intraoperative Imaging in Finding Pancreatic Cancer in Patients Undergoing Surgery

Pancreatic Adenocarcinoma

United States
HiberCell, Inc.

Terminated

Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer (PRIMUS)

Colorectal Cancer

United States, Puerto Rico, Germany, France
Merck KGaA, Darmstadt, Germany

Completed

Study to Evaluate the Efficacy and Safety of FOLFOX-4 Plus Cetuximab Versus UFOX Plus Cetuximab. (FUTURE)

Previously Untreated Metastatic Colorectal Cancer

France, Italy, Poland, Germany, Hong Kong, Austria, Brazil, Israel, Greece, Argentina, Thailand, Belgium, Australia, Mexico
Charite University, Berlin, Germany

Completed

InductionChemo-Radio-Antibody-Treatment (ICRAT)

Squamous Cell Carcinoma of the Neck | Squamous Cell Carcinoma of the Head

Germany
Arbeitsgemeinschaft medikamentoese Tumortherapie
Merck Sharp & Dohme LLC

Completed

Biomarker Directed Treatment in Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

Austria
Poitiers University Hospital

Completed

Study of Skin Toxicity of Cetuximab: Find a Link Between Skin Inflammation and Tumor Response

Metastatic Colon Cancer

France
Cliniques universitaires Saint-Luc- Université...
Merck Sharp & Dohme LLC; Merck Serono International SA

Completed

Neoadjuvant Cetuximab in HNSCC Combined With Curative Surgery (CHIRON)

Head and Neck Cancer

Belgium
Copenhagen University Hospital at Herlev

Unknown

Treatment of Patients With Advanced Rectum Cancer With Capecitabine and Oxaliplatin Before, Under and After Radiation and With Adding Cetuximab to K-RAS Wild-type Patients

Rectum Cancer

Denmark
AstraZeneca
Hutchison MediPharma

Recruiting

Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib (SAVANNAH)

Carcinoma

Denmark, Spain, United States, Taiwan, Vietnam, Canada, Korea, Republic of, Brazil, India, Japan, Italy, Puerto Rico, France, Chile
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Completed

Cetuximab in Treating Patients With Precancerous Lesions of the Upper Aerodigestive Tract

Head and Neck Cancer | Precancerous Condition

United States, Canada
Heidelberg University

Completed

Radiation Plus Cetuximab in Locally Advanced Non-Small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung

Germany
Cancer Institute and Hospital, Chinese Academy...

Recruiting

The Efficacy and Safety of Modified XELOX(mXELOX) Plus Cetuximab vs FOLFOX Plus Cetuximab in RAS and BRAF WT mCRC Pts

Colo-rectal Cancer

China
Assistance Publique - Hôpitaux de Paris
GERCOR - Multidisciplinary Oncology Cooperative Group

Completed

FOLFOX-Cetuximab-radiotherapy for the Treatment of Esophageal Cancer (FOLFOX)

Esophageal Cancer Stage III

France
Shanghai Ninth People's Hospital Affiliated to...

Recruiting

Neoadjuvant and Adjuvant Toripalimab and Cetuximab in Patients With Recurrent, Resectable Squamous Cell Carcinoma of Head and Neck: a Prospective, Single-arm,Phase II Study

Patients With Locally Recurrent Resectable Head and Neck Squamous Cell Carcinoma

China
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Cisplatin With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic or Recurrent Head and Neck Cancer

Head and Neck Cancer

United States, Puerto Rico, South Africa
Eben Rosenthal

Terminated

Cetuximab IRDye800 Study as an Optical Imaging Agent to Detect Cancer During Surgical Procedures

Head and Neck Cancer

United States
Memorial Sloan Kettering Cancer Center
Eli Lilly and Company; National Comprehensive Cancer Network

Completed

Cetuximab at Either 500 or 750 mg/m2 Every Other Week for Recurrent or Metastatic Head and Neck Squamous Cell Cancer

Squamous Cell Cancer | Head and Neck

United States
Gynecologic Oncology Group
Bristol-Myers Squibb; National Cancer Institute (NCI)

Completed

Cetuximab and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer

Cervical Cancer

United States
Centre Hospitalier of Chartres
Hospital of Chartres- France

Completed

Study of Cetuximab in Squamous Cell Carcinoma of the Skin Expressing EGFR (CTXSCC)

Skin Diseases | Carcinoma, Squamous Cell

France
UNICANCER

Completed

Treatment After Irinotecan-based Frontline Therapy: Maintenance With Erbitux (in Patients wtRAS mCRC) (TIME)

Metastatic Colorectal Cancer

France
Grupo Español de Tratamiento de Tumores de Cabeza...

Completed

TPF Plus Radiotherapy and Cetuximab to Avoid Total Laryngectomy in Patients With Larynx Cancer

Head and Neck Cancer

Spain

Search clinical trials for: cetuximab and savolitinib

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Macedonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations